Cargando…

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by deposition of insoluble amyloid fibrils in the myocardium, resulting in cardiac structural and functional abnormalities and ultimately heart failure. Disease frequency is reportedly lower in wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruno, Marianna, Castaño, Adam, Burton, Arianna, Grodin, Justin L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769788/ https://www.ncbi.nlm.nih.gov/pubmed/32794090 http://dx.doi.org/10.1007/s10741-020-10010-8

Ejemplares similares

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

US CARDIOLOGIST AND PATIENT PERSPECTIVES ON COVID-19 TELEHEALTH PRACTICES FOR PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
por: Mitter, Sumeet, et al.
Publicado: (2021)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy
por: Huda, Ahsan, et al.
Publicado: (2021)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
por: He, Shan, et al.
Publicado: (2019)

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
por: Lauppe, Rosa, et al.
Publicado: (2022)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan
por: Yamada, Toshihiro, et al.
Publicado: (2020)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States
por: Bhambri, Rahul, et al.
Publicado: (2023)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy
por: Knoll, Katharina, et al.
Publicado: (2023)

Stumbling across transthyretin amyloid cardiomyopathy during diagnostic work-up for stomach cancer
por: Lee, Hyun-Ki, et al.
Publicado: (2023)

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
por: Tomasoni, Daniela, et al.
Publicado: (2023)

Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
por: Vong, Camille, et al.
Publicado: (2021)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
por: Takashio, Seiji, et al.
Publicado: (2023)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model
por: Bruno, Marianna, et al.
Publicado: (2023)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center
por: Mitchell, Joshua D, et al.
Publicado: (2022)

Diagnosis of wild‐type transthyretin amyloid cardiomyopathy in Japan: red‐flag symptom clusters and diagnostic algorithm
por: Inomata, Takayuki, et al.
Publicado: (2021)

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia
por: Lin, Weiqin, et al.
Publicado: (2022)

Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients
por: Eldhagen, Per, et al.
Publicado: (2023)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2mkeo1ud75k8d9lh2sluam1rek